Polyethylene glycol 3350 in occasional constipation: A one-week, randomized, placebo-controlled, double-blind trial

Table 4 Summary of treatment-emergent adverse events, safety population n (%)

Summary	Treatment group
	PEG 3350	Placebo
Total subjects	102	101
Total subjects with an adverse event	14 (13.7)	17 (16.8)
Nervous system disorders	11 (10.8)	11 (10.9)
Headache	11 (10.8)	11 (10.9)
Migraine	1 (< 1.0)	0
Musculoskeletal and connective tissue disorders	3 (2.9)	2 (2.0)
Back pain	0	2 (2.0)
Neck pain	2 (2.0)	0
Arthralgia	1 (< 1.0)	0
Gastrointestinal disorders	0	4 (4.0)
Nausea	0	2 (2.0)
Abdominal distension	0	1 (< 1.0)
Dyspepsia	0	1 (< 1.0)
Infections and infestations	1 (< 1.0)	1 (< 1.0)
Nasopharyngitis	1 (< 1.0)	0
Sinusitis	0	1 (< 1.0)
Psychiatric disorders	1 (< 1.0)	1 (< 1.0)
Insomnia	1 (< 1.0)	1 (< 1.0)
Respiratory, thoracic, and mediastinal disorders	2 (2.0)	0
Nasal congestion	1 (< 1.0)	0
Pharyngolaryngeal pain	1 (< 1.0)	0

PEG: Polyethylene glycol.